Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canertinib in advanced NSCLC
NCT00050830Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2003
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 8
01
Overview
A Phase 2 trial of canertinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started Jan 2003; status: completed.
02
Drugs
canertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00050830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00050830.